Table 1 Characteristics of MRSA bloodstream infections in patients hospitalized in the ICU compared with other wards
Characteristic | Non-ICU (n = 116) | ICU (n = 16) | P value |
|---|---|---|---|
Age, years (median, IQR) | 70.5 (56–77) | 59 (56–68) | 0.07 |
Males (%) | 82/116 (70.7) | 10/16 (62.5) | 0.50 |
Charlson score (median, IQR) | 6 (3–7) | 2 (1–4) | <0.001 |
CVC (>72 h) (%) | 58/116 (50) | 12/16 (75) | 0.05 |
Other intravascular devices (>72 h) (%) | 8/116 (6.9) | 2/16 (12.5) | 0.35 |
Urinary catheter (>72 h) (%) | 40/116 (34.5) | 14/16 (87.5) | <0.001 |
Antimicrobial therapy (<30 days) (%) | 50/116 (43.1) | 10/16 (62.5) | 0.14 |
Source of infection | |||
Unknown | 46/116 (39.6) | 0/16 (0) | 0.002 |
CVC | 12/116 (10.3) | 3/16 (18.8) | 0.53 |
Pulmonary | 12/116 (10.3) | 1/16 (6.3) | 1.00 |
Endocarditis | 15/116 (12.9) | 8/16 (50) | 0.001 |
Skin and soft tissue | 12/116 (10.3) | 3/16 (18.7) | 0.53 |
Other | 19/116 (4.3) | 1/16 (6.3) | 1.00 |
CVC removal (%) | 42/58 (72.4) | 12/12 (100) | 0.06 |
Source control (%) | 22/70 (31.4) | 12/16 (75) | 0.003 |
Hospitalization, days (median, IQR) | 30 (18–44) | 56 (25–116) | 0.01 |
Acquisition (%) | |||
Community acquired | 2/116 (1.7) | 0/16 (0) | 1.00 |
Health-care associated | 40/116 (34.5) | 0/16 (0) | <0.001 |
Hospital-acquired | 74/116 (63.8) | 16/16 (100) | 0.003 |
Septic shock | 22/116 (19) | 1/16 (6.3) | 0.37 |
Infectious disease consultation (%) | 53/116 (45.7) | 4/16 (25) | 0.11 |
Empirical antimicrobial therapy (%) | 110/116 (94.8) | 16/16 (100) | 1.00 |
Daptomycin | 7/104 (6.7) | 0/12 (0) | 0.35 |
Glycopeptides | 24/104 (23.1) | 1/12 (8.3) | 0.46 |
Therapy duration, days (median, IQR) | 16 (7-22) | 18 (14-27) | 0.31 |
Adequate initial therapy (%) | 30/116 (25.9) | 2/16 (12.5) | 0.39 |
7-day mortality (%) | 27/116 (23.3) | 3/16 (18.8) | 0.69 |
30-day mortality | 42/116 (36.2) | 5/16 (31.3) | 0.7 |